NASDAQ New Lows: Lexicon Pharmaceuticals (NASDAQ:LXRX), Exelixis (NASDAQ:EXEL), HMS Holdings (NASDAQ:HMSY), Antares Pharma (NASDAQ:ATRS)

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), stock is trading up 25% on volume of 200 after the company reported positive results in a clinical trial of type 1 diabetes drug LX4211. The trial found that the drug successfully reduced insulin use and improved glycemic control in patients with poorly controlled diabetes. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), shares after opening at $1.79 moved to $1.86 on last trade day and at the end of the day closed at $1.55. Company price to sales ratio in past twelve months was calculated as 361.97 and price to cash ratio as 6.19. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), showed a negative weekly performance of 5.49%.

Exelixis, Inc. (NASDAQ:EXEL) on Mar. 25 announced that the Independent Data Monitoring Committee (IDMC) notified the company that a planned interim analysis of the COMET-1 phase 3 pivotal trial has been completed, and that the IDMC recommended the trial proceed to its final analysis. Exelixis continues to anticipate top-line data from COMET-1 in 2014. COMET-1 is a randomized, double-blind, controlled trial designed to enroll 960 patients with mCRPC who have progressed after treatment with docetaxel, abiraterone and/or enzalutamide. All patients in the trial have bone metastases and there is no limit to the number or type of prior treatments. Exelixis, Inc. (NASDAQ:EXEL), shares fell 1.48% in last trading session and ended the day on $3.32. Exelixis, Inc. (NASDAQ:EXEL), return on equity ratio is recorded as -150.50% and its return on assets is -42.00%. Exelixis, Inc. (NASDAQ:EXEL), yearly performance is -31.40%.

On March 25, 2014, HMS Holdings Corp (NASDAQ:HMSY), announced that its third party liability contract with the Commonwealth of Massachusetts, Executive Office of Health and Human Services (EOHHS), has been extended and expanded. The contract scope includes other health insurance identification, verification, referral processing, and maintenance; enhanced Premium Assistance program enrollment and maintenance services; and retroactive recovery for the MassHealth program, and expands some of these services for the Commonwealth’s Health Safety Net program. HMS Holdings Corp (NASDAQ:HMSY),shares moved down 3.96% in last trading session and was closed at $16.50, while trading in range of $ 15.10 – 17.00. HMS Holdings Corp (NASDAQ:HMSY), year to date (YTD) performance is -27.31%.

Antares Pharma (NASDAQ:ATRS) was downgraded by investment analysts at TheStreet from a “hold” rating to a “sell” rating in a note issued to investors on Monday, ARN reports. Antares Pharma Inc (NASDAQ:ATRS), weekly performance is -9.94%. On last trading day company shares ended up $2.99. Antares Pharma Inc (NASDAQ:ATRS), distance from 50-day simple moving average (SMA50) is -27.64%. Analysts mean target Price for the company is $6.25.